Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Gorelick

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Cancer Discovery|October 2, 2020
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase InhibitorsEmiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, et al.
Science (New York, N.Y.)|December 4, 2004
Mineralogy at Meridiani Planum from the Mini-TES Experiment on the Opportunity RoverP R Christensen, M B Wyatt, T D Glotch, et al.
Cancer Discovery|December 7, 2019
Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast CancerLillian M Smyth, Sarina A Piha-Paul, Helen H Won, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Cancer Discovery|October 2, 2020
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase InhibitorsEmiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, et al.
Science (New York, N.Y.)|December 4, 2004
Mineralogy at Meridiani Planum from the Mini-TES Experiment on the Opportunity RoverP R Christensen, M B Wyatt, T D Glotch, et al.
Cancer Discovery|December 7, 2019
Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast CancerLillian M Smyth, Sarina A Piha-Paul, Helen H Won, et al.
Pageof 3